# This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

> **NCT03780725** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Head and Neck Neoplasms

## Interventions

- **DRUG:** BI 754111
- **DRUG:** [89Zr]Zr-BI 754111
- **DRUG:** BI 754091

## Key facts

- **NCT ID:** NCT03780725
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-22
- **Primary completion:** 2020-02-19
- **Final completion:** 2020-12-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780725, "This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03780725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*